Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11

The AWARD-11 trial demonstrated the safety and efficacy of dulaglutide (DU) once weekly doses of 3 mg and 4.5 mg compared to DU 1.5 mg in patients with type 2 diabetes (T2D) inadequately controlled with metformin monotherapy. This exploratory post hoc analysis of AWARD-11 assessed the effect of dula...

Descripción completa

Detalles Bibliográficos
Autores principales: Frias, Juan Pablo, Bonora, Enzo, Cox, David A, Kwan, Anita, Raha, Sohini, Bethel, Angelyn, Malik, Raleigh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090394/
http://dx.doi.org/10.1210/jendso/bvab048.678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090394/
http://dx.doi.org/10.1210/jendso/bvab048.678

Ejemplares similares